39 results on '"Intorcia, M"'
Search Results
2. PCR203 A Qualitative Study of the Health-Related Quality of Life Impact of Geographic Atrophy on Patients
3. POSA29 A New Patient-Focused Progression Model for Geographic Atrophy
4. PUK3 TREATMENT EFFECTS IN SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE: A SYSTEMATIC LITERATURE REVIEW
5. PUK6 A COST-EFFECTIVENESS MODEL FOR SECONDARY HYPERPARATHYROIDISM IN NON-DIALYSIS CHRONIC KIDNEY DISEASE
6. Impact of Skeletal-Related Events on Anti-Tumor Therapy Pattern in Patients with Bone Metastases from Prostate Cancer
7. Incremental Healthcare Resource use and Costs Associated with Skeletal-Related Events in Patients with Bone Metastases from Solid Tumors
8. Medication-taking behaviour in Bulgarian women with postmenopausal osteoporosis treated with denosumab or monthly oral bisphosphonates
9. Persistence, Compliance And Bisphosphonate Switching In Patients With Multiple Myeloma (MM) In Germany
10. Occurrence Of Skeletal-Related Events (SRE) In Patients With Solid Tumors (ST) And Multiple Myeloma (MM) In Germany: Early Versus Late Initiation of Sre Preventative Agents (SPA)
11. Patient Characteristics, Skeletal Related Events (SRE) And Renal Impairment (RI) In Patients With Multiple Myeloma (MM): A Patient Chart Audit In EU5
12. Denosumab And Bisphosphonates Persistence, Compliance And Switch In Patients With Solid Tumors (ST) And Bone Metastases (BM)
13. Skeletal-Related Events (SRES) and Renal Function in Patients with Symptomatic Multiple Myeloma (MM): Results from Belgium, France, Germany, Italy, Spain, Switzerland and The United Kingdom
14. GRAND-4: the German retrospective analysis of long-term persistence in women with osteoporosis treated with bisphosphonates or denosumab
15. Prevalence Of Renal Impairment In Patients With Multiple Myeloma: Analysis Of Real-World Database
16. Grand-4: The German Retrospective Analysis on Persistence in Women with Osteoporosis Treated with Bisphosphonates or Denosumab
17. Persistence with denosumab and persistence with oral bisphosphonates for the treatment of postmenopausal osteoporosis: a retrospective, observational study, and a meta-analysis
18. Systematic Review and Meta-Analysis of Persistence With Denosumab in Patients With Osteoporosis
19. Increased Bone Mineral Density (Bmd) In Postmenopausal Women With Osteoporosis (Op) Receiving Two Denosumab Injections In Routine Clinical Practice In Bulgaria
20. The Cost of Osteoporotic Fractures in the Romanian Postmenopausal Women Population
21. Persistence & Compliance to Treatment for Osteoporosis in Postmenopausal Women in Hungary: A Retrospective Cohort Study
22. Compliance Protects Against Fracture in Women with Postmenopausal Osteoporosis in Hungary
23. Treatment Persistence in Swedish Women Initiating Denosumab Treatment for Postmenopausal Osteoporosis
24. PMS55 A Retrospective Cohort Study of Persistence & Compliance to Treatment for Osteoporotic Men in Hungary
25. PMS54 A Retrospective Cohort Study of Persistence & Compliance to Treatment for Osteoporosis in Postmenopausal Women in Hungary
26. PMS56 Impact of Compliance on Fracture Risk for Osteoporosis in Postmenopausal Women in Hungary
27. PMS19 The Economic Burden of Post-Menopausal Osteoporosis and Related Fractures in Greece
28. PMS35 A Cost-Effectiveness Analysis of Denosumab for the Treatment of Post-Menopausal Osteoporosis in Greece
29. GRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonates
30. Persistencia en el tratamiento para la osteoporosis en pacientes posmenopáusicas en el ámbito de la Atención Primaria
31. PMS24 OSTEOPOROSIS COSTS IN ITALY. INTERIM RESULTS OF THE BLOCK STUDY
32. PIH30 PERSISTENCE TO POSTMENOPAUSAL OSTEOPOROSIS (PMO) TREATMENTS IN A REGION OF SPAIN
33. PMS66 GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE AND ASSOCIATED RISK OF FRACTURES IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES
34. PMS68 GRAND: THE GERMAN RETROSPECTIVE COHORT ANALYSIS ON NON-ADHERENCE IN OSTEOPOROSIS PATIENTS TREATED WITH ORAL BISPHOSPHONATES
35. IN1 COST EFFECTIVENESS ANALYSIS OF REYATAZ® VERSUS KALETRA® IN THE TREATMENT OF NAÏVE HIV PATIENTS IN ITALY
36. PMS36 COST OF THERAPY OF TUMOR NECROSIS FACTOR BLOCKING AGENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
37. PMS39 COST-UTILITY OF ABATACEPT IN RHEUMATOID ARTHRITIS PATIENTS WITH AN INSUFFICIENT RESPONSE OR INTOLERANCE TO ANTI-TNF THERAPY IN ITALY: A PROBABILISTIC SENSITIVITY ANALYSIS
38. PIN14 USING A DECISION SIMULATION MODELTO EVALUATE THE COST-EFFECTIVENESS OF THE TREATMENT OF NUCLEOSIDE-NAÏVE HBE-ANTIGEN NEGATIVE CHB PATIENTS IN ITALY WITH ENTECAVIR AND TEN OF OVIR
39. PMS62 DISCONTINUATION RATE OF THE IST AND IIND ANTI-TUMOR NECROSIS FACTORTHERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.